CONSHOHOCKEN, PA -- (Marketwired) -- 04/25/13 -- NuPathe Inc.(PATH) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent application 12/074,101 entitled "Implants for the Treatment of Dopamine Associated States." This application relates to a biodegradable polymer implant capable of delivering a dopamine modulating compound, such as ropinirole, with little or no initial burst and maintaining an effective plasma level for a specified period of time. Given this action, NuPathe(PATH) expects the patent to issue within the next few months. Once issued, it will provide patent protection into July 2028 for NP201, NuPathe's(PATH) long-term biodegradable ropinirole implant for the treatment of Parkinson's disease. NuPathe(PATH) has additional licensed patent applications pending in the U.S. and other territories for NP201.
"We are pleased with the USPTO's allowance and believe a strong patent portfolio for NP201 is an important valuable component of the value proposition as we seek development partners for this program," said Armando Anido, chief executive officer of NuPathe(PATH). "While obtaining this patent is important, we remain focused on securing commercial partners and preparing for the launch of ZECUITY."
This is the big drug they need to propel forward.. Parkinson's is unfortunately such a major illness that the market keeps a close eye on it. This patent will strengthen us greatly. Our futures look well partner or not